Business NewsPR NewsWire • FDA Approves Merck's VICTRELIS™ (boceprevir), First-in-Class Oral Hepatitis C Virus (HCV) Protease Inhibitor

FDA Approves Merck's VICTRELIS™ (boceprevir), First-in-Class Oral Hepatitis C Virus (HCV) Protease Inhibitor

FDA Approves Merck's VICTRELIS™ (boceprevir), First-in-Class Oral Hepatitis C Virus (HCV) Protease Inhibitor

WHITEHOUSE STATION, N.J., May 14, 2011 /PRNewswire/ -- Merck (NYSE: MRK) (known as MSD outside the United States and Canada) announced today that the U.S. Food and Drug Administration (FDA) has approved VICTRELIS™ (boceprevir), the company's innovative new medicine for the treatment of chronic

View More : http://www.prnewswire.com/news-releases/fda-approves-mercks-victrelis-boceprevir-first-in-class-oral-hepatitis-c-virus-h...
Releted News by prnewswire
Snoopy Lands at Valleyfair
FDA Approves Merck's VICTRELIS™ (boceprevir), First-in-Class Oral Hepatitis C Virus (HCV) Protease Inhibitor
RPJ Housing Announces Compliance Initiative
Pharmasset to Present at Two Upcoming Conferences
Yanglin Soybean, Inc. Reports First Quarter 2011 Financial Results